Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | ATPase family, AAA domain containing 5 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | Get druggable targets OG5_139225 | All targets in OG5_139225 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0689 | 0.4289 | 1 |
Leishmania major | choline/Carnitine o-acyltransferase-like protein | 0.0689 | 0.4289 | 1 |
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | 0.0979 | 0.6592 | 1 |
Onchocerca volvulus | 0.0147 | 0 | 0.5 | |
Loa Loa (eye worm) | choline/Carnitine O-acyltransferase | 0.0231 | 0.0661 | 0.0661 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0455 | 1 |
Echinococcus granulosus | geminin | 0.0205 | 0.0455 | 0.106 |
Echinococcus multilocularis | geminin | 0.0205 | 0.0455 | 0.069 |
Echinococcus granulosus | carnitine O palmitoyltransferase 2 | 0.0231 | 0.0661 | 0.154 |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0231 | 0.0661 | 1 |
Leishmania major | carnitine palmitoyltransferase-like protein | 0.0231 | 0.0661 | 0.154 |
Onchocerca volvulus | 0.0147 | 0 | 0.5 | |
Echinococcus multilocularis | carnitine O palmitoyltransferase 2 | 0.0231 | 0.0661 | 0.1002 |
Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.0231 | 0.0661 | 0.0661 |
Echinococcus granulosus | carnitine O palmitoyltransferase 1 liver | 0.0689 | 0.4289 | 1 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0689 | 0.4289 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0455 | 1 |
Onchocerca volvulus | 0.0147 | 0 | 0.5 | |
Onchocerca volvulus | 0.0147 | 0 | 0.5 | |
Echinococcus multilocularis | carnitine O palmitoyltransferase 1, liver | 0.0689 | 0.4289 | 0.6507 |
Trypanosoma cruzi | carnitine O-palmitoyltransferase II, putative | 0.0231 | 0.0661 | 0.154 |
Loa Loa (eye worm) | hypothetical protein | 0.1409 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.8584 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 9.285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 11.5821 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.3535 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.